MNPR NASDAQ
Monopar Therapeutics Inc.
1W: -3.2%
1M: -14.2%
3M: -33.1%
YTD: +8.8%
1Y: -11.9%
3Y: +3050.9%
5Y: +188.2%
$71.84
+1.30 (+1.84%)
Weekly Expected Move ±6.9%
$61
$66
$71
$76
$80
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Monopar Therapeutics Inc. would be worth roughly what it owes.
Total debt $108K against a stock market value of $482.2M.
Distance to default 14.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $54K (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' 36.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Monopar Therapeutics Inc. would be worth roughly what it owes.
Total debt $108K against a stock market value of $482.2M.
Distance to default 14.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $54K (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' 36.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-04-20
Earliest Filing
2025-09-24
Latest Filing
partner: 5
Counterparties (Filed by MNPR)
5 relationshipsCompanies named in MNPR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Morgan Stanley & Co. LLC | MS-PL | partner | Underwriter representing the underwriters in the sale of common stock and pre-funded warrants | 2025-09-24 | View |
| Leerink Partners LLC | — | partner | Underwriter representing the underwriters in the sale of common stock and pre-funded warrants | 2025-09-24 | View |
| Barclays Capital Inc. | BCLYF | partner | Underwriter representing the underwriters in the sale of common stock and pre-funded warrants | 2025-09-24 | View |
| Alexion, AstraZeneca Rare Disease | — | partner | Monopar entered into an exclusive worldwide license agreement for the Wilson disease drug candidate ALXN-1840. | 2024-10-24 | View |
| JonesTrading Institutional Services LLC | — | partner | Sales agent for the Capital on DemandTM Sales Agreement | 2022-04-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-22 | Regulation FD; Exhibits | View | |
| 2026-06-30 | Regulation FD; Exhibits | View | |
| 2026-06-26 | Regulation FD; Exhibits | View | |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-05-29 | Regulation FD; Exhibits | View | |
| 2026-05-19 | Regulation FD; Exhibits | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-04-20 | Regulation FD; Exhibits | View | |
| 2026-03-27 | Earnings Release; Exhibits | View | |
| 2026-03-02 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-09-24 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-09-15 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-07 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR